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Abstract
Staphylococcus aureus is a serious human pathogen and antibiotic resistant, community-
associated strains, such as the methicillin resistant S. aureus (MRSA) strain USA300, con-
tinue to spread. To avoid resistance, anti-virulence therapy has been proposed where toxic-
ity is targeted rather than viability. Previously we have shown that norlichexanthone, a small
non-reduced tricyclic polyketide produced by fungi and lichens, reduces expression of hla
encoding α-hemolysin as well as the regulatory RNAIII of the agr quorum sensing system in
S. aureus 8325–4. The aim of the present study was to further characterise the mode of
action of norlichexanthone and its effect on biofilm formation. We find that norlichexanthone
reduces expression of both hla and RNAIII also in strain USA300. Structurally, norlichex-
anthone resemblesω-hydroxyemodin that recently was shown to bind the agr two compo-
nent response regulator, AgrA, which controls expression of RNAIII and the phenol soluble
modulins responsible for human neutrophil killing. We show that norlichexanthone reduces
S. aureus toxicity towards human neutrophils and interferes directly with AgrA binding to its
DNA target. In contrast toω-hydroxyemodin however, norlichexanthone reduces staphylo-
coccal biofilm formation. Transcriptomic analysis revealed that genes regulated by the
SaeRS two-component system are repressed by norlichexanthone when compared to
untreated cells, an effect that was mitigated in strain Newman carrying a partially constitu-
tive SaeRS system. Our data show that norlichexanthone treatment reduces expression of
key virulence factors in CA-MRSA strain USA300 via AgrA binding and represses biofilm
formation.
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Introduction
Staphylococcus aureus is a serious human bacterial pathogen that causes infections ranging
from minor skin and soft tissue infections to osteomyelitis, sepsis and necrotizing pneumonia
[1]. In the early 1990’s highly invasive community-associated methicillin resistant S. aureus
(CA-MRSA) strains emerged such as USA300 [2,3]. This strain has now become one of the
predominant CA-MRSA clones and it is evolving towards resistance against several antibiotic
classes [4]. With the increase in problems associated with antimicrobial resistance, alternative
treatments are being considered. One option is anti-virulence therapy where compounds are
sought to reduce virulence rather than pathogen viability [5,6]. In S. aureus, the agr quorum
sensing system controls expression of numerous virulence factors in response to cell density,
including α-hemolysin and the phenol-soluble modulins (PSMs), that contribute particularly
to the virulence of CA-MRSA [7]. The agr P2 transcript encodes a two-component signal
transduction system composed of the response regulator, AgrA, and the sensor histidine
kinase, AgrC that responds to secreted autoinducing peptide (AIP). AgrA controls expression
of the divergently transcribed RNAIII expressed from the P3 promoter as well as of the PSMs
[8,9]. Other two-component systems also modulate virulence including the auto-regulated
SaeRS that responds to external stimuli such as pH, NaCl, sub-inhibitory concentrations of
antimicrobial peptides and human skin fatty acids [10–12]. In addition to virulence, both agr
and SaeRS influence biofilm formation in S. aureus, with agr acting through production of the
PSMs [13] and SaeRS by repressing production of extracellular proteases degrading proteins of
importance to biofilm formation [14].
Several natural compounds have been found to target virulence gene expression in S. aureus
including the solonamides, which are cyclic peptides isolated from a marine Gram-negative
bacterium, that structurally resemble the AIPs and competitively interfere with AIP binding to
AgrC [15,16]. Small molecules also interfere with RNAIII expression but in most cases the
mode of action is unknown [17]. However, a group of compounds has recently been found to
bind directly to AgrA and interfere with the DNA binding [18,19,20]. Two of these molecules,
known as savirin and ω-hydroxyemodin, reduced RNAIII and psm expression and reduced
infection in a mouse soft tissue model [19,20]. Structurally ω-hydroxyemodin is highly similar
to norlichexanthone that we previously isolated from Penicillium algidum (IBT 24414) as an
inhibitor of S. aureus virulence gene expression [21]. Xanthones are small, non-reduced tricy-
clic polyketides occurring in higher plant families, lichen and fungi and they have various bio-
logical activities such as being antimicrobial, anti-tumorigenic, antiulcer, and CNS-depressing
[22]. Here we aimed to evaluate how norlichexanthone affects virulence gene expression in the
serious CA-MRSA strain USA300 and examine its effect on biofilm formation.
Materials and Methods
Bacterial strains and growth conditions
S. aureus strains used in this study were strain 8325–4 [23], Newman [24], FPR3757 (USA300)
a multidrug resistant CA-MRSA isolate (obtained from ATCC, Sweden) implicated in out-
breaks of skin and soft tissue infection [25], PC322, hla::lacZ [26], PC203, spa::lacZ [26],
SH101F7, rnaIII::lacZ [27], and the β-lactamase reporter strain RN10829 [28]. Bacteria were
grown in Tryptone Soya Broth (TSB), Oxoid, (1:10 volume/flask ratio), at 37˚C with shaking at
200 rpm. Norlichexanthone was purchased from Synthon-Lab Ltd., Bumazhnaya st. 17, office
400, 190020, St-Petersburg, Russia.
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Transcriptional analysis
For RNA isolation cells were inoculated at OD600 = 0.02–0.03. Norlichexanthone was added
at OD600 = 0.4. Samples for RNA purification were taken at OD600 = 0.7 and/or 2.0 for strain
USA300 and strain Newman, and 1 hour after addition of norlichexanthone for strain 8325–4.
Cells were harvested and total RNA was extracted using RNeasy kit (Qiagen) in accordance
with the manufacturer’s instructions. RNA quantity and quality were measured on a Nano-
Drop ND-1000 spectrophotometer by absorbance (A260, A260/A280 and A260/A230 ratio
respectively) and by gel electrophoresis. Northern blot analysis was performed as described
previously using equal amounts of total RNA for each lane [29]. Probes targeting hla, spa,
RNAIII, agrA and psmα transcripts were amplified by PCR using the primers (from TAG
Copenhagen A/S, Denmark) indicated in Table 1, resulting in probe lengths of 311 bp (hla),
719 bp (spa), 316 bp (RNAIII), 584 bp (agrA) and 176 bp (psmα) respectively. For quantifica-
tion of transcript levels by RT-qPCR residual DNA was removed by treating RNA preparations
with DNase I, RNase-Free (Thermo Scientific) according to the manufacturer’s instructions
except for an extension of the incubation step to one hour. The RNA was reverse transcribed
to cDNA using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems),
according to the manufacturer’s instructions. To control for DNA contamination,
reactions containing no reverse transcriptase were used as negative controls in subsequent
amplifications. The cDNA samples were diluted ten-fold and 5 μl was used as template DNA
for quantitative PCR of hla, spa, RNAIII, saeR, lukF, sbi and coa using FastStart Essential
DNA Green Master and a LightCycler1 96 instrument (both Roche). Results were calculated
using the comparative cycle threshold method, in which the amount of target mRNA was
normalized to that of the reference genes ileS and pyk. Reactions were performed in triplicate,
and results are presented as the means and standard deviations of the data obtained from 3
biological replicates. Primers used for RT-qPCR and Northern blot analysis are shown in
Table 1.
Table 1. Primers used in this study.
Gene Forward primer Reverse primer
hla CTGTCGCTAATGCCGCAGATTCTG CTTCTTCGCTATAAACTCTATATTGACCAGC
spa CAAACGGCACTACTGCTGAC CATGGTTTGCTGGTTGCTTC
RNAIII GCACTGAGTCCAAGGAAACTAAC AAGCCATCCCAACTTAATAACC
saeR CCAAGGGAACTCGTTTTACG GCATAGGGACTTCGTGACC
lukF GCTTATCAGGTGGAGGTAATGG TGTGCTTCAACATCCCAACC
sbi AAGACAGCAAGAACCCAGACC CAAACTTGTTGGCTTCTATCAGG
ileS ACATACAGCACCAGGTCACG CGCCTTCTTCAGTAAATACACC
pyk AGGTTGAACTCCCCAAACAA GCAGCCCAAGATTACAAAAA
coa ACTAAGGAAGTATACGATCTCGTATCTG GATTGTCTGTATCTCCAAGGATTAAGTC
brnQ GGACCATTTTTCGCCTTACC CATGCAATCACAAAGAAGACG
agrAc GTGTACACATATGGATAATAGCGTTGAAACGATTGAATTAAAACG GTAGGCACTCGAGTTATATTTTTTTAACGTTTCTCACCGATG
Northern blot primers
hla GGG TTA GCC TGG CCT TCA GCC GGG TGC CAT ATA CCG GGT TC
spa GGG GGT GTA GGT ATT GCA TCT G GGG GCT CCT GAA GGA TCG TC
RNAIII GGG GAT CAC AGA GAT GTG ATG GGG CAT AGC ACT GAG TCC AAG G
agrA Ctgataatccttatgaggtgc cgatgcatagcagtgttc
psmα tatcaaaagcttaatcgaacaattc ccccttcaaataagatgttcatatc
doi:10.1371/journal.pone.0168305.t001
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Human neutrophil lysis assay
The ability of S. aureus FPR3757 (USA300) to lyse human neutrophils was tested as described
previously [16]. Briefly, sterile filtered supernatants from 7 h and 22.5 h S. aureus LAC/
FPR3757 (USA300) cultures were grown in 10 mL TSB media/ 100 mL Erlenmeyer flasks, with
a start inoculum OD600 = 0.02 and either DMSO (control) or norlichexanthone added to the
cultures. Neutrophils were isolated by Ficoll-hypaque purification from fresh heparinized
human blood from healthy volunteers according to the regulations of National Committee on
Health Research Ethics in Denmark. Blood samples were obtained from volunteer donors by
persons not involved in the described analyses according to the regulation of the National Com-
mittee on Health research ethics in Denmark (using blood for assessment of effects of microor-
ganisms or microbial components does not require approval from the committee by law no 593
of June 14, 2011). Written consent was obtained from the voluntary donors. Blood was collected
for this specific type of analyses. De-identification was done at collection by the person drawing
the blood before handing the samples over to the persons performing the analyses.
S. aureus aggregation assay
S. aureus strain 8325–4 was inoculated in TSB (1 mL per well) in a 24-well plate to a start
OD600 = 0.02. Norlichexanthone dissolved in DMSO was added from the beginning to a final
concentration of 0.5, 1, 5 and 10 μg/mL. No compound and DMSO were used as controls. The
plates were incubated 8½ hours at 37˚C, with gentle shaking. To quantify the results, the cul-
tures were allowed to sediment for 30 min and the supernatants collected for OD determina-
tion at 600 nm, as a lower supernatant OD is indicative of aggregation while single cells remain
in suspension increasing the OD. Statistical analysis was performed using the student’s t-test.
Static biofilm assay
The assay was performed as described [30] with minor modifications. In brief, a starter culture
of strain 8325–4 was grown in TSB to OD600 = 0.5. From this culture 50 μL was withdrawn
and diluted 10-fold in a 0.9% NaCl solution. 5 μL were inoculated into wells of a 96-well micro-
titer plate containing 200 μl TSB. Norlichexanthone was added to final concentrations of 0,
0.5, 1, 5 and 10 μg/mL. DMSO and no treatment were used as controls. The plates were incu-
bated for 20 hours at 37˚C without shaking. The biofilm was washed twice with (200 μL) 0.9%
NaCl, dried and stained with (125 μL) Crystal Violet (0.1%) for 30 min followed by 3x wash
with (200 μL) 0.9% NaCl. For quantification purposes the biofilm was solubilized in 96% Etha-
nol and the absorbance measured at 590 nm using an ELISA plate reader. Statistical analysis
was performed using the student’s t-test.
Activity of norlichexanthone on P3::blaZ reporter strains
P3 promoter activity was measured in strain RN10829 expressing in trans either wild type
AgrC (pagrC-I-WT) or a constitutively active variant (pEG11) using a β-lactamase assay as pre-
viously described [16]. Briefly, strains were grown in triplicates to OD600 = 0.4–0.5, after
which they were split into two cultures and either 5 μg/ml norlichexanthone or DMSO was
added. The AgrC-I-WT strain was supplemented with spent medium from strain 8325–4 con-
taining AIP-I at indicated concentrations. Cells were further incubated at 37˚C shaking at 200
rpm. At indicated time points OD600 was recorded and samples were withdrawn and frozen
immediately (-80˚C). β-lactamase activity was determined by adding a final concentration of
0.1 mM nitrocefin (Oxoid) to the samples, and subsequently measuring OD486 over time at
Norlichexanthone Reduces Virulence Gene Expression and Biofilm Formation in S. aureus
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37˚C allowing a calculation of arbitrary activity units based on Vmax (ΔOD486/time) relative to
the sample cell density.
Expression analysis by DNA microarray
S. aureus strain USA300 was inoculated to an OD600 = 0.02 in Erlenmeyer flasks containing
TSB (1/10 flask volume) while shaking at 200 rpm at 37˚C. At OD600 = 0.4 either norlichex-
anthone (to a final concentration of 5 μg/mL) or DMSO (control) was added. Sampling for
RNA purification was made at OD600 = 2.0. Biological triplicates were performed. RNA prep-
aration for microarray experiments was carried out using the Agilent FairPlay III kit with Cy3
as the only dye. Arrays were scanned with an Agilent 2-micron scanner and feature data
obtained using Agilent’s Feature Extraction software. Data were further processed with the
Bioconductor software suite [31]. Quantile-base normalization was performed as implemented
in the Limma software package [32]. Differential expression was analyzed using Limma (linear
models for microarray data) by applying the TREAT methodology [33] to test whether the
true differential expression is greater than a given threshold value, (here selected as 1) when
examining log2-fold changes.
Recombinant protein expression and purification of AgrAc
The C-terminal, DNA binding domain of AgrA (AgrAc) from 8325–4 was PCR amplified
(using the AgrAc forward and reverse primers) and cloned between the NdeI and XhoI sites of
pET28b to create a recombined plasmid having an in frame fusion of AgrAc with His-tag
(Table 1). Expression and purification of AgrAc was carried out as previously described with
minor modifications [34]. E.coli strain BL21 (DE3) strain expressing AgrAc was pre-cultured
in 50 ml LB at 37˚C overnight. The pre-culture was diluted (1:100) in fresh 1 L LB and cultured
at 37˚C to OD600 = 0.4–0.6, and then 1 mM of isopropyl β-D-1-thiogalactopyranoside was
added. After 20 hours at 16˚C, the cells were harvested and lysed in the presence of a protease
inhibitor cocktail in a sonicator (8 seconds, stop 5 seconds, 200 cycles). The cell lysate was cen-
trifuged and supernatant was collected (12000 rpm, 30 min at 4˚C). Expressed protein was
purified from the frozen cells with His-Trap column (Novagen). The purified protein was
pooled and loaded onto PD-10 column (GE Healthcare) to remove imidazole and desalted,
then was supplemented with 20% glycerol and stored at -80˚C.
Electrophoretic Mobility Shift Assays (EMSA)
The P2-P3 probe (49 bp duplex DNA) covering the agr P2 and P3 promoter region was pre-
pared by annealing TTACATTTAACAGTTAAGTATTTATTTCCTCTAGTTAAGCAATATAATG
with its complementary oligonucleotide in 25 mM sodium phosphate, 100 mM NaCl, 10 mM
DTT at pH 5.8 and purified by size exclusion chromatography using a Superdex 75 column.
The DNA probe was mixed with recombined AgrAc (100 μM) in 10 μL reaction mixture con-
sisting of 10 mM TrisHCl (pH 7.4), 50 mM KCl, 5 mM MgCl2, 0.5 μg poly (dI-dC) and either
compound or DMSO loading control. After 20 min incubation at 25˚C, the samples were
mixed with 10 μL of the loading buffer mixture consisting of 10 mM TrisHCl (pH 7.4), 50
mM KCl, 5 mM MgCl2, 20% glycerol. Samples including AgrAc, DNA probe, vehicle and/or
compound (0~100 μg/mL) were loaded in TBE buffer containing 10 mM dithiothreitol. The
mixtures were analyzed by 4.5% native polyacrylamide gel electrophoresis (120 V for 60 min
for pre-run, 10 mA for 20 min, 80 V for 40 min for sample separation) in 1x TBE buffer. The
gels were stained with 2 μL SYBR gold (life technologies) in 50 mL 1x TBE buffer. The digital
images were acquired and quantified using a phosphor screen (Dark Reader transilluminator
DR-88X).
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Results and Discussion
Norlichexanthone modulates RNAIII, hla and spa expression
Previously we used transcriptional reporter gene fusions to show that norlichexanthone
extracted from Penicillium algidum decreases hla and RNAIII expression while enhancing the
expression of spa in the laboratory strain 8325–4 [21]. When examined by Northern blot analy-
sis we confirmed these findings for both strain 8325–4 (Fig 1A) and the CA-MRSA, USA300
(Fig 1B) with the increase in spa transcription being prominent in 8325–4. The expressional
changes observed upon norlichexanthone treatment were verified by RT-qPCR (S1 Fig).
Approximately 5 μg/mL is required to modulate virulence gene expression (Fig 1A) and at this
concentration, growth of S. aureus is essentially unaffected by the compound (data not shown).
Norlichexanthone interferes with agr downstream of AgrC activation by
AIP, most likely by binding to AgrA
Structurally, norlichexanthone is almost identical to ω-hydroxyemodin and bears some resem-
blance to savirin (S2 Fig) both of which were demonstrated to bind directly to the DNA bind-
ing domain of AgrA [19,20]. We thus hypothesized that due to the structural similarities of
norlichexanthone with these two compounds, norlichexanthone could also be binding to
AgrA and thus functioning downstream of the AgrC receptor. To support this hypothesis, we
employed a reporter strain in which the P3 promoter that normally drives RNAIII expression
has been fused to the blaZ gene and is uncoupled from activation by the natural AIP-AgrC
interaction [16]. In this strain the genes encoding the AIP (agrB and agrD) have been deleted
and thus the strain relies on externally added AIPs. Corroborating the previous transcriptional
data, we observed a significant repression of RNAIII promoter activity (approximately 50%)
by norlichexanthone in a strain expressing a wild type AgrC that requires AIP addition for
activity (Fig 2A). Importantly, we also noted that the relative repression appeared to be inde-
pendent of the AIP concentration used, which is contrary to what was observed for the com-
petitive inhibitor, solonamide B [16], thus implying that the repression is not linked to the
Fig 1. Norlichexanthone affects expression of spa, hla and RNAIII. Expression of hla, spa and RNAIII
was examined by Northern blot analysis with probes recognizing the transcripts in strain 8325–4 (A) or
USA300 (B) treated with in A): 1: No treatment, 2: DMSO (negative control), 3: Norlichexanthone 50 μg/mL
(dissolved in DMSO), 4: Norlichexanthone 5 μg/mL, 5: Norlichexanthone 0.5 μg/mL, 6: Norlichexanthone
0.05 μg/mL, 7: Norlichexanthone 0.005 μg/mL added at OD600 = 0.4, and sampled after 1 hour. B)
Norlichexanthone 5 μg/mL or DMSO or nothing was added at OD600 = 0.4. RNA was purified from samples
taken at OD600 = 0.7 (lanes 1–3) and 2.0 (lanes 4–6). 1: no treatment, 2: DMSO, 3: Norlichexanthone 5 μg/
mL, 4: no treatment, 5: DMSO, 6: Norlichexanthone 5 μg/mL.
doi:10.1371/journal.pone.0168305.g001
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Fig 2. Norlichexanthone reduces RNAIII expression in an AIP concentration-independent manner and also in a mutant with a
constitutively active AgrC receptor. (A) Activity of the P3-blaZ promoter in a strain expressing a wild type, AIP-inducible AgrC receptor
in presence or absence of 5 μg/ml norlichexanthone (Nor). The data represent the mean and standard deviation of the β-lactamase
activity obtained from 3 biological replicates at different AIP concentrations (5, 13, and 20%) at time points 30 and 60 minutes. In all
conditions, the effect of norlichexanthone is statistically significant (P<0.001, two-tailed student’s t-test). (B) Accumulated activity of the
P3-blaZ promoter in a strain expressing a constitutively active AgrC receptor in presence or absence of 5 μg/ml norlichexanthone (Nor).
The β-lactamase activity was measured at 30 and 60 minutes and subtracted the BlaZ activity present already at time 0 to infer the effect
on P3 expression after compound addition. The data represent the mean and standard deviation from 3 biological replicates with the
effect of norlichexanthone being statistically significant (P<0.01 at both time points, two-tailed student’s t-test).
doi:10.1371/journal.pone.0168305.g002
Norlichexanthone Reduces Virulence Gene Expression and Biofilm Formation in S. aureus
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AgrC-AIP interaction Corroborating this interpretation, norlichexanthone is also able to sig-
nificantly reduce RNAIII promoter activity in a strain expressing a constitutively active AgrC
receptor (Fig 2B) ranging from 25–40% at the two time points assayed. These results suggest
that norlichexanthone represses the agr regulon downstream of AgrC and possibly via binding
to AgrA.
To experimentally address the possibility that norlichexanthone interferes with AgrA bind-
ing to DNA, we expressed the C-terminal DNA binding domain of AgrA (AgrAc) and exam-
ined its effect on AgrAc binding to the P2-P3 probe carrying AgrA binding sites using the
electrophoretic mobility shift assay (EMSA) (Fig 3). The result shows that norlichexanthone at
concentrations higher than 12.5 μg/ml prevents AgrA from binding to a fragment containing
the binding sites present in the agr P2 and P3 region. This data therefore confirms our initial
hypothesis that norlichexanthone interferes with agr-controlled virulence gene expression via
inhibition of AgrA binding to the agr P2 and P3 promoter region.
Norlichexanthone reduces S. aureus toxicity against human neutrophils
Human neutrophils are one of the primary defences against S. aureus infections and particu-
larly CA-MRSA strains such as USA300 are adept at inducing rapid neutrophil lysis [35,36].
Neutrophil lysis is mediated in part by the PSMs whose expression is controlled by AgrA
[37,38]. To address if norlichexanthone affects S. aureus mediated neutrophil lysis we exam-
ined culture supernatants of USA300 grown either in the presence or absence of compound.
As shown in Fig 4, norlichexanthone reduced the ability of USA300 to lyse human neutrophils
Fig 3. Norlichexanthone interferes with AgrA binding to DNA. Samples including AgrAc, DNA probe, and/or
compound were loaded in TBE buffer containing 10 mM dithiothreitol. Assays including the P2-P3 49 bp probe
were analyzed in 4.5% native polyacrylamide gels. Lanes: 1. Size marker; 2. P2-P3 probe alone; 3. Probe and
norlichexanthone (Nor) in the absence of AgrAc protein; 4. 100 uM I-d (potential hit compound and positive
binding control); 5–10: norlichexanthone (Nor) increased by two-fold concentrations from 0–100 μg/ml.
doi:10.1371/journal.pone.0168305.g003
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Fig 4. Norlichexanthone protects against S. aureus mediated neutrophil lysis. Sterile filtered
supernatants of S. aureus USA300 (S.a.) cultures grown for 7 hours with either norlichexanthone at 5 μg/mL
or 10 μg/mL or DMSO (control) were added to isolated human neutrophils. The control supernatant where
only DMSO was added was examined in 1-fold, 3-fold and 9-fold dilutions (A). Undiluted (1:1) supernatants
from norlichexanthone (norlic) treated cultures are shown together with untreated supernatant in (B) and
3-fold dilutions (1:3) are shown in (C). Lysis was monitored by lactate dehydrogenase (LDH) release. Data
represents 3 independent experiments, using the average of triplicate wells from each experiment. Asterisk
indicates norlichexanthone treated cultures resulting in lysis statistically significant from the corresponding
control by one-way ANOVA with Dunnett’s posttest. *, p<0.05, **, p<0.01; ***, p<0.001.
doi:10.1371/journal.pone.0168305.g004
Norlichexanthone Reduces Virulence Gene Expression and Biofilm Formation in S. aureus
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when applied at a concentration that reduces hla and RNAIII expression. Correlating with the
reduced neutrophil lysis of norlichexanthone treated cells, we observed that norlichexanthone
treatment also reduced agrA expression but only in the exponential growth phase
(OD600 = 0.7) and did not significantly affect psm-α expression at OD600 = 2.0 (S3 Fig). Thus,
norlichexanthone reduced S. aureus mediated neutrophil lysis and the effect is likely mediated
by other toxins than the PSM-α.
Norlichexanthone reduces biofilm formation and aggregation
The success of S. aureus as a pathogen is in part attributed to its ability to form biofilm and col-
onize biotic and abiotic surfaces. Aggregation of unattached cells also appears to be important
and in both biofilm and aggregation, antibiotic therapy is highly inefficient [39–41]. To deter-
mine if norlichexanthone influences biofilm formation and aggregation we assayed these prop-
erties in strain 8325–4 that forms biofilm and is prone to aggregation [39,42]. In the presence
of 5 μg/ml norlichexanthone both aggregation (Fig 5A) and biofilm formation (Fig 5B) were
greatly reduced while being unaffected by the solvent, DMSO. Furthermore, no CFU reduc-
tion was observed (Fig 5C) indicating that these results were not due to compound toxicity,
but rather a direct effect on aggregation and biofilm properties. Among the factors that influ-
ence biofilm formation is agr [43]. However, as agr dysfunction generally is associated with
increased biofilm formation [43,44] our data indicate that interaction with another regulatory
pathway than agr is mediating the effect of norlichexanthone on biofilm formation.
The Sae regulon is repressed by norlichexanthone
In an effort to better understand the effect of norlichexanthone on S. aureus also with respect
to the above results, we analyzed global gene expression in strain USA300 incubated in the
presence of 5 μg/ml norlichexanthone for 2 h until an OD600 of 2.0 was reached. Using 3 bio-
logical replicates we found 219 genes to be more than 2-fold affected (122 genes with increased
expression and 97 genes with decreased expression) compared to the DMSO-treated control
cells (S1 Table). Among the genes most prominently affected were gltAB, ilvABCDH, sirABC,
leuABCD,metEHNX, oppABCDF, dapABH, ggt, hisABDGH, thrBC, isdACDEF, seg, srtB,
hsdMRS, and lysC, which were all more than 2-fold up-regulated; and hla, hlb, hlgC, fib, map,
clfA, lukS, sbi, epiEFG, lip2, carA, pyrBCEFP, sasA, saeRS, lukF, sspAB, aur, phoP, psmα1234 and
arlR which were all more than 2-fold down-regulated.
Interestingly, among the genes affected by norlichexanthone is a group that is regulated by
the two component transcriptional regulatory system, SaeRS namely lukF, sbi, hlgC, fib, hla,
hlb, and saeRS [44–46] and another group under the control of the stringent response regula-
tor, CodY (gltAB, ilvABCDH, leuBCD, hisABDGH, pyrBCEFP, dapABH, lysC, oppABCDF) [47].
Sae has been implicated as a key downstream regulator of virulence gene expression in S.
aureus controlling genes being involved in toxicity, immune evasion and bacterial cell adhe-
sion and even biofilm formation [11,14]. While we were unable to verify the effect of norli-
chexanthone on the CodY regulated genes, the effect on the SaeRS regulated genes was
confirmed by quantitative RT-PCR with primers recognizing saeR, lukF and sbi of the SaeRS-
regulon, and brnQ giving the log2 values of -3.6±0.4; -2.3±0.4; -3.4±0.3; -1.8±0.3 respectively
for the indicated genes. These results show that in the presence of norlichexanthone, the SaeRS
regulated genes are significantly repressed.
To further implicate the SaeRS system in response to norlichexanthone we examined the
effect of the compound in strain Newman that naturally harbors a mutation in the saeS. This
mutation allows constitutively active expression of some SaeRS controlled genes including coa
encoding coagulase, while leaving other SaeRS controlled genes such as hla unaffected by the
Norlichexanthone Reduces Virulence Gene Expression and Biofilm Formation in S. aureus
PLOS ONE | DOI:10.1371/journal.pone.0168305 December 22, 2016 10 / 16
Fig 5. Aggregation and biofilm formation are significantly reduced by norlichexanthone. Strain 8325–
4 was cultivated in the presence of DMSO, 0.5, 1, 5 μg/mL or 10 μg/mL norlichexanthone, and incubated 8½
hours at 37˚C. (A) Quantification of aggregation. After sedimentation, the supernatants of the cultures were
measured for optical density at 600 nm. (B) Dilutions were inoculated into a 96-well microtiter plate containing
200 μL TSB. Norlichexanthone was added to a final concentration of 0.5, 1, 5 and 10 μg/mL. No inoculate, no
treatment and DMSO (compound vehicle) were used as controls. The plate was incubated for 20 hours at
37˚C without shaking. Biofilm formation was quantified by 0.1% crystal violet staining and OD measurement at
590 nm. (C) Culture CFUs were obtained to eliminate possibility of compound toxicity attributing to reduction
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mutation [46]. When examining expression of coa and hla by qPCR in the presence or absence
of norlichexanthone we observed that norlichexanthone caused a reduction in hla expression
in both strains (although not to the same extent) while coa expression was reduced by the com-
pound in USA300 but not in strain Newman (Fig 6). This result together with the microarray
data, supports that norlichexanthone may be affecting the Sae system either directly or indi-
rectly. However, as norlichexanthone did not alter expression of protease genes as deduced
from the DNA microarray analysis our results do not support a Sae mediated effect on biofilm
formation [14].
Conclusion
Our results show that norlichexanthone reduces virulence gene expression in the CA-MRSA
strain USA300 and that it modulates virulence gene expression by interfering with at least two
different key virulence gene regulons; the agr and the SaeRS two component systems. We suc-
cessfully show that reduction in RNAIII expression, and thus RNAIII-controlled virulence fac-
tors, is a result of direct interaction of norlichexanthone with AgrA, thus blocking AgrA’s
ability to bind to the P2-P3 promoter region of the agr locus. Our microarray data reveal a sub-
stantial decrease in sae controlled genes in norlichexanthone exposed USA300, implicating a
role in SaeRS inhibition. We also show that norlichexanthone not only reduces neutrophil
lysis by S. aureus, but also inhibits both biofilm formation and aggregation, all of which are
central to S. aureus’s success as a human pathogen. Although the exact mechanisms involved
in the inhibition of these key virulence traits by norlichexanthone remain to be ascertained, we
have nevertheless demonstrated that a small molecule can be an efficient repressor of virulence
gene expression and biofilm formation. We thus postulate that such compounds with dual
of aggregation. Each bar represents the average of 3 replicates and the error bars represent the standard
deviation.
doi:10.1371/journal.pone.0168305.g005
Fig 6. Expression of coa and hla monitored by quantitative RT-PCR. Expression was monitored in
strains USA300 (FPR3757) and Newman by quantitative RT-PCR. Depicted are fold-changes of the
transcripts observed upon treatment with 5 μg/ml norlichexanthone relative to DMSO from samples taken at
OD600 = 2.0. The data represent the mean and standard deviation from 3 biological replicates.
doi:10.1371/journal.pone.0168305.g006
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actions can be of particular interest when seeking new treatment options for S. aureus related
infections in the future.
Supporting Information
S1 Fig. Expressional changes of RNAIII, hla and spa conferred by norlichexanthone. Strain
8325–4 was grown exponentially to OD600 = 0.4 where either 5 μg/mL norlichexanthone or
DMSO was added. Transcript levels after 1 hour treatment were determined by RT-qPCR.
Depicted mean fold-changes (+/- standard deviation) by norlichexanthone are based upon 3
biological replicates.
(TIF)
S2 Fig. Structure of nolirchexanthone, ω-hydroxyemodin and savarin.
(TIF)
S3 Fig. Norlichexanthone reduces psmα and agrA expression. Strain USA300 were grown
exponentially to OD600 = 0.4 where either 5 μg/mL norlichexanthone (nor), DMSO or noth-
ing was added. RNA was purified from samples collected at OD600 = 0.7 and 2.0, and analyzed
by Northern blotting where equal amounts of RNA was loaded. The membrane was probed
with radioactive labeled probes targeting agrA and psmα.
(TIF)
S1 Table. Transcriptome analysis of USA300 exposed to norlichexanthone. Cells were
grown in TSB and treated with 5 μg/mL norlichexanthone or corresponding amount of
DMSO at OD600 = 0.4. Data is based on biological triplicates, sampled at OD600 = 2.0. Fold
regulation indicates norlichexanthone treated cells relative to DMSO treated cells.
(DOCX)
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